A5007751144- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Cytokine Signaling Pathways and Interactions
- Ovarian cancer diagnosis and treatment
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Radiopharmaceutical Chemistry and Applications
- Immune Cell Function and Interaction
- Venous Thromboembolism Diagnosis and Management
- Genetic factors in colorectal cancer
- PARP inhibition in cancer therapy
- Colorectal Cancer Screening and Detection
- Circular RNAs in diseases
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Chemotherapy-related skin toxicity
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
Central University Hospital of Asturias
2004-2022
MD Anderson Cancer Center Madrid
2019
Abstract Background The Janus kinase/signal transducer and activator of transcription ( JAK ‐ STAT ) signaling pathway plays a key role in the systemic inflammatory response many cancers, including colorectal cancer CRC ). This study evaluated addition ruxolitinib, potent 1/2 inhibitor, to regorafenib patients with relapsed/refractory metastatic . Methods In this two‐part, multicenter, phase 2 study, eligible adult had adenocarcinoma colon or rectum; an Eastern Cooperative Oncology Group...
A proportion of patients with metastatic colorectal cancer (mCRC) are still able to continue active therapy after their progression fluoropyrimidines, oxaliplatin, and irinotecan regimens. Studies suggest that gemcitabine fluoropyrimidines synergic antimetabolites. The purpose was evaluate gemcitabine-capecitabine (Gem-Cape) in heavily pretreated mCRC thus assess possible predictive factors for progression-free survival (PFS) overall (OS).This analysis performed on 119 evaluable irinotecan,...
3527 Background: A 15-20% of pts diagnosed mCRC do not qualify to receive PChT as first-line therapy, due age and/or comorbidities, and their optimal treatment strategy has been defined. REG is an oral multikinase inhibitor indicated for pretreated mCRC. We aimed assess the efficacy safety a single agent in setting this frail unfit patient population. Methods: Phase II, single-arm study PChT, pts. Inclusion criteria: ≥ 18 years, ECOG PS ≤ 2, adequate organ function, at least one following:...
MicroRNAs (miRs) are frequently altered in colorectal cancer (CRC) and can be used as prognostic factors.To confirm stage III CRC patients a reported miR signature that was associated to the presence of metastatic disease. To correlate expression with microsatellite instability (MSI) mutations RAS BRAF.miR-21, miR-135a, miR-206, miR-335 miR-Let-7a analyzed by RT-qPCR 150 out 329 analyze MSI BRAF mutations. Association disease free survival (DFS) overall (OS) analyzed. Data confirmed...
663 Background: The JAK-STAT pathway plays a role in the systemic inflammatory response CRC. Rux, potent JAK1/2 inhibitor, was evaluated r/r mCRC pts. Methods: After safety run-in (Rux 20 mg BID + Re 160 QD), pts were randomized to Rux 15 or placebo (Pb) QD. could be titrated BID. phase included Substudy 1 (S1, with C-reactive protein [CRP] > 10 mg/L) and 2 (S2, CRP ≤ mg/L). Primary endpoint: OS. Results: well tolerated (n = 11). 396 (S1: n 175; S2: 221). Median age vs (v) Pb groups: 62 v...
3559 Background: Mutational analysis of RAS in mCRC has showed an improvement patient (pts) selection for anti-EGFR drugs. The standard techniques (Techs) have analytical sensitivity (Sns) 1-5%. Digital PCR (dPCR) can detect mutated alleles at .05-.1% Sns, but it is unclear if this offers a clinical advantage. Objective:To compare the Sns and feasibility to point mutations KRAS, NRAS, BRAF PIK3CAby Cobas, Therascreen assays quantitative dPCR (Fluidigm), correlate them with progression-free...
626 Background: CRC patients treated with anti-EGFR having skin reactions tend to have a better outcome regardless of the presence mutations in RAS. This fact, repeated various antibodies makes us think that basal immunology, or its ability react these proteins is actually responsible for this phenomenon. We initiated an exploratory study identify which parameters/immunological pathways might be related reactions. Methods: Seric levels immunoglobulins (IgG, IgA, and IgM) complement factors...
e14049 Background: Although in use for almost 30 years, the clinical value of CEA as marker choice monitoring response advanced colorectal cancer (ACRC) to systemic therapy is not clearly established and no study has investigated usefulness patients (pts) treated with new drugs angiogenesis inhibitors. The aim this was prospectively evaluate relationship between serum CEA, computed tomography (CT) scan, gold standar test, ACRC by calculating sensitivity (S), specificity (Sp), positive...
15119 Background: Since the approval of Bevacizumab (Bev) for its use in first line setting metastatic colorectal cancer (mCRC) treatment, it has become one standard drugs used combinations. To date there are no markers to identify patients (pts) that can most benefit from this drug, moreover, data clinical trials indicate almost every patient drug so, decision whether or not a particular patient, is taken on an individual basis, by patient. We have analysed profile pts treated with Bev all...
Background: The RECIST criteria may be limited in assessing response to biologic agents such as bevacizumab (BVZ). Computed tomography-based morphologic (CTMC) might an alternative evaluate these cases. aim of this trial was the correlation overall objective responses evaluated by with CTMC and pathologic (pR) after resection liver metastases from colorectal cancer. Methods: Patients ≤ 4 resectable CLM, no prior chemotherapy for metastatic disease, received 3 cycles capecitabine/oxaliplatin...